| Similar Articles |
|---|
 |
BusinessWeek
September 4, 2006
Gene G. Marcial |
A Super Outlook For SuperGen Biotechs have not fared well in this fickle market.   |
The Motley Fool
September 3, 2004
Charly Travers |
MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions. |
The Motley Fool
October 18, 2007
Brian Lawler |
MGI's Quiet Gains The specialty pharma notches a healthy third-quarter and should keep performing well into the future. Investors, take note. |
The Motley Fool
December 11, 2007
Brian Lawler |
The MGI Deal Makes Sense MGI Pharma announces it is being acquired by Japanese pharma giant Eisai for $3.9 billion. |
The Motley Fool
November 30, 2007
Brian Lawler |
MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S. |
The Motley Fool
July 24, 2007
Brian Lawler |
MGI Flies Shares of MGI Pharma rise after positive second-quarter results and a bright outlook for the coming months. |
The Motley Fool
October 23, 2006
Brian Lawler |
MGI's Anonymous Growth If there's a value stock in the pharma world, this may be it. |
The Motley Fool
July 3, 2008
Brian Lawler |
Celgene Savors the Schadenfreude Bad news for a rival is a bonanza for drugmaker Celgene. |
Chemistry World
September 6, 2013
Phillip Broadwith |
Otsuka to buy Astex for $886 million Japanese firm Otsuka has agreed to buy the Anglo-American Astex Pharmaceuticals for $886 million in cash. |
The Motley Fool
August 12, 2010
Jordan DiPietro |
7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels. |
